Cochrane · systematic review · CD001909
Lamotrigine add‐on therapy for drug‐resistant focal epilepsy
Panebianco, M, Bresnahan, R, Marson, AG · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings: lamotrigine versus placebo for drug‐resistant focal epilepsy
Population: participants with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency (ITT analysis) Summary of findings: lamotrigine vs placebo | RR 1.8 [1.45, 2.23] | 12 studies · 1322 participants | Moderate Downgraded: imprecision |
Treatment withdrawal Summary of findings: lamotrigine vs placebo | RR 1.11 [0.91, 1.37] | 14 studies · 1806 participants | Moderate Downgraded: imprecision |
Ataxia Summary of findings: lamotrigine vs placebo | RR 3.34 | 12 studies · 1525 participants | Moderate Downgraded: imprecision |
Dizziness Summary of findings: lamotrigine vs placebo | RR 1.76 | 13 studies · 1768 participants | Moderate Downgraded: inconsistency |
Fatigue Summary of findings: lamotrigine vs placebo | RR 0.82 | 12 studies · 1552 participants | Moderate Downgraded: imprecision |
Nausea Summary of findings: lamotrigine vs placebo | RR 1.81 | 12 studies · 1486 participants | Moderate Downgraded: imprecision |
Diplopia Summary of findings: lamotrigine vs placebo | RR 3.79 [2.15, 6.68] | 3 studies · 944 participants | Moderate Downgraded: imprecision |
Comparison
Population: participants with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency ‐ ITT analysis | RR 1.8 [1.45, 2.23] | 12 studies · 1322 participants | Moderate Downgraded: imprecision |
Treatment withdrawal | RR 1.11 [0.91, 1.37] | 14 studies · 1806 participants | Moderate Downgraded: imprecision |
Ataxia | RR 3.34 | 12 studies · 1525 participants | High |
Diplopia | RR 3.79 | 3 studies · 944 participants | High |
Dizziness | RR 2 | 13 studies · 1768 participants | Moderate Downgraded: imprecision, inconsistency |
Fatigue | RR 0.82 | 12 studies · 1552 participants | Moderate Downgraded: imprecision |
Nausea | RR 1.81 | 12 studies · 1486 participants | Moderate Downgraded: imprecision |
Comparison
Population: participants with drug‐resistant partial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency ‐ ITT analysis | RR 1.8 [1.45, 2.23] | 12 studies · 1322 participants | High |
Treatment withdrawal | RR 1.11 [0.9, 1.36] | 14 studies · 1805 participants | High |
Ataxia | RR 3.34 | 12 studies · 1524 participants | Moderate Downgraded: imprecision |
Dizziness | RR 2 | 13 studies · 1767 participants | High |
Fatigue | RR 0.82 | 12 studies · 1551 participants | High |
Nausea | RR 1.81 | 12 studies · 1486 participants | High |